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of anagen onset (McDowall et al., 2008).
Follistatin gene expression was higher
in the skin of younger mice. Further,
follistatin levels were increased in older
skin grafts following transplantation onto
younger mice. As follistatin is a secreted
molecule, it may be responsible for the
reactivation of hair cycling in telogenic
donor skin when grafted onto younger
recipients. Strikingly, follistatin-releasing
beads were sufficient to convert hair
follicles in telogen into anagen when
placed on the skin of young mice.
Whether this effect can be recapitulated
in older mice in telogen retention
remains to be seen.
These results support an emerging
understanding that aging in skin is not
fully a cell autonomous phenomenon.
However, as intriguing as these findings
are, they raise several new questions.
The mechanisms by which follistatin
or other extrafollicular signals activate
stem cells in the hair bulge are
unknown. As follistatin is a known
BMP antagonist (McDowall et al.,
2008), and as younger mice express
higher levels of follistatin, it is tempting
to speculate that younger mice are less
sensitive to the anagen-inhibitory effects
of BMP2. In addition, whether follistatin
is the only molecule in young skin
capable of rejuvenating older follicles
is not clear. Finally, the reason why
waves of hair regeneration dissipate in
the center of larger skin grafts remains
uncertain. It will be interesting to
determine whether this reflects intrinsic
hair follicle defects or deficiencies
in extrinsic signals. These questions
aside, the present study is a compel-
ling demonstration that extrafollicular
stimuli govern differences in hair
renewal capacities in young and old
mice. At least when it comes to hair
cycling, you really are as young as your
neighbors.
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Clinical Implications
 Hair follicles in younger mice cycle more frequently compared with those
in older mice.
 Factors extrinsic to hair follicles can reactivate hair cycling in dormant
older skin.
 The secreted protein follistatin enhances hair follicle cycling, pointing to a
potential therapeutic strategy for alopecia.
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Toxic Interaction between Th2
Cytokines and Staphylococcus aureus
in Atopic Dermatitis
Jeffrey B. Travers1,2
Patients with atopic dermatitis (AD) are commonly colonized/infected with
Staphylococcus aureus, and this bacterium is known to worsen the dermatitis.
In this issue, Brauweiler et al. demonstrate a newly discovered mechanism by
which Th2 cytokines involved in AD augment the toxicity of the lytic staphylo-
coccal protein alpha toxin. This review presents mechanisms by which Th2
cytokines may interact with S. aureus to the detriment of the dermatitis.
Journal of Investigative Dermatology (2014) 134, 2069–2071. doi:10.1038/jid.2014.122
The vast majority (B90%) of individuals
with active atopic dermatitis (AD) are
colonized/infected with Staphylococcus
aureus, a species implicated in worsen-
ing the skin disease. The propensity of
these patients to harbor staphylococcal
bacteria is thought to be due in part to
the inhibitory effects of Th2 cytokines
(IL-4, IL-13) on antimicrobial peptide
production. Through this mechanism
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and the inhibitory effects of these
cytokines on barrier formation, Th2
cytokines provide an environment con-
ducive to bacterial growth.
Given their clinical importance in the
management of AD, the mechanisms by
which staphylococcal bacteria worsen
AD are areas of active study. Staphylo-
coccal bacteria trigger inflammation
from direct infection of cell types such
as keratinocytes. Staphylococcal pro-
ducts can also exert profound effects
via binding to specific receptors. With
examples listed in Table 1, these agents
include exotoxins that act as superanti-
gens, Staphylococcal protein A (SPA),
the cell wall product lipoteichoic
acid (LTA), and cytolytic toxins such as
staphylococcal alpha toxin and delta
toxin. The exact importance of these
staphylococcal products in AD asso-
ciated with infection is, as yet,
unknown.
Superantigens including Toxic Shock
Syndrome Toxin-1 and Staphylococcal
enterotoxin B have significant pro-
inflammatory effects via their abilities
to bind to major histocompatibility com-
plex II molecules and activate large
numbers of T cells. Relevant to AD,
many patients harbor specific IgE anti-
bodies that recognize these large glob-
ular proteins (Leung et al., 1993). Thus,
superantigen-producing S. aureus could
generate type I allergic responses via
this mechanism. SPA, a surface protein,
acts as an important, yet complex, viru-
lence factor contributing to the success
of this pathogen by interfering with
immune clearance and by modulating
inflammation in part via its ability to
activate the tumor necrosis factor recep-
tor 1 (TNFR1) directly. Although this
would be expected to engender a pro-
inflammatory response, recent studies
have suggested that through triggering
of TNFR1 shedding SPA can actually
exert anti-inflammatory effects by the
removal of local TNF-a (Giai et al.,
2013). The cell wall component LTA
has also been implicated in AD inflam-
mation. Recent studies indicate that
large (microgram) amounts of this toll-
like receptor 2 and platelet-activating
factor receptor agonist are found on the
skin of children with secondarily infected
AD (Travers et al., 2010).
Staphylococcal bacteria also com-
monly express at least four cytolytic
toxins that appear to have important
roles in virulence and in host damage/
inflammation. For example, recent stu-
dies have determined that delta toxin is
a potent inducer of mast cell degranula-
tion (Nakamura et al., 2013). Although
IgE is not necessary for delta toxin–
mediated mast cell degranulation, the
presence of this allergy-associated anti-
body on mast cell results in exaggerated
toxin responses (Nakamura et al., 2013).
Thus, AD patients with high levels of IgE
in response to Th2 cytokine overactivity
would be especially susceptible to delta
toxin–mediated effects.
Staphylococcal alpha toxin is one of
the most prominent and destructive
cytolytic toxins. This pore-forming toxin
can act on cell membranes directly, and
this process appears to be facilitated via
binding to membrane sphingomyelin
molecules. Alpha toxin treatment of
keratinocytes induces cytokine produc-
tion, as well as induces cellular death
(Ezepchuk et al., 1996; Travers et al.,
2003). As reported in this issue,
Brauweiler et al. (2014) provide evi-
dence that Th2 cytokine exposure can
increase the sensitivity of keratinocytes
to alpha toxin–mediated cell death.
Alpha toxin treatment of skin biopsies
derived from AD patients resulted
in increased levels of cell death in
Table 1. Mechanisms by which staphylococcal products can modulate AD and the role of Th2 cytokines
Staphylococcal mediator Effect on AD skin lesion Th2 cytokine effect References
Alpha toxin Increased keratinocyte cell death and worsening of lesion;
increased cytokine production
Increased toxicity via inhibiting filaggrin,
acid sphingomyelinase
Brauweiler et al., 2013,
2014
Delta toxin Increased mast cell degranulation and worsening of lesion Increased effect via increased IgE
production
Nakamura et al., 2013
Superantigen (staphylococcal
enterotoxin B, toxic shock
syndrome toxin-1y)
Increased mast cell degranulation and release of cytokines via
triggering specific IgE molecules and worsening of lesion
Increased effect via increased IgE
production
Leung et al., 1993
Staphylococcal protein A Unclear effects; increased inflammation via signaling through
TNFR1 versus anti-inflammatory effects via removal of TNF-a
Not known Giai et al., 2013
Lipoteichoic acid Increased inflammation via signaling through TLR2 and platelet-
activating factor receptor and worsening of lesion
Not known Travers et al., 2010
Abbreviations: AD, atopic dermatitis; TNF, tumor necrosis factor; TNFR1, tumor necrosis factor receptor 1.
Clinical Implications
 Staphylococcal infection is a known trigger for worsening of atopic
dermatitis skin disease, likely through multiple mechanisms.
 These studies describe a novel mechanism by which Th2 cytokines
associated with atopic dermatitis patients can worsen the effects of alpha
toxin, a major cytotoxic protein produced by Staphylococcus aureus.
 The ability to block the effects of alpha toxin via the use of exogenous acid
sphingomyelinase or phosphocholine provides the impetus for novel
therapeutics to treat atopic dermatitis patients with chronic skin staphy-
lococcal infections.
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comparison with normal skin. The role
of Th2 cytokines was then confirmed
using keratinocyte primary cultures trea-
ted with IL-4/IL-13. In contrast, gamma-
INF treatment did not modulate alpha
toxin–mediated cytotoxicity. IL-4/IL-13
augmentation of alpha toxin–mediated
cytotoxicity was shown to be due to the
ability of these Th2 cytokines to
decrease the levels of acid sphingo-
myelinase, the enzyme that cleaves
sphingomyelin into ceramide and phos-
phocholine. The ability of exogenous
sphingomyelinase or phosphocholine
to reverse the alpha toxin toxicity not
only confirmed the mechanisms but also
provided the rationale for possible
therapeutics.
The authors also demonstrated in a
recent companion report that the epider-
mal barrier protein filaggrin also has an
important role in the regulation of acid
sphingomyelinase, and that deficiency in
filaggrin predisposes for increased alpha
toxin–mediated cytotoxicity (Brauweiler
et al., 2013). Relevant to Th2 cytokines,
IL-4 and IL-13 have also been shown to
inhibit filaggrin expression (Howell
et al., 2009). Thus, one can envision a
positive feedback pathway by which
Th2 cytokines not only provide a permis-
sive environment for S. aureus but also
enhance the effects of staphylococcal
products. These findings are compatible
with the notion that strategies that
remove bacteria, such as dilute bleach
baths, can improve AD skin disease
(Huang et al., 2009).
In summary, the interplay between
Th2 cytokines and S. aureus has high
significance for understanding AD.
Indeed, the majority of AD flares
involve S. aureus in some capacity.
New insights into the exact mechanisms
by which staphylococcal exposure can
worsen AD could allow improved and
novel treatments for this common skin
disease and its significant morbidities.
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A Possible Role for IL-17A in
Establishing Th2 Inflammation in
Murine Models of Atopic Dermatitis
Nikhil Dhingra1,2 and Emma Guttman-Yassky1,3
Atopic dermatitis (AD) is associated with the effects of T helper type 2 (Th2) and
Th22 cytokines. Recent studies, however, have also implicated Th17 in acute AD.
Functional studies of Th2 and Th22 cytokines revealed their roles in generating
molecular changes during AD; IL-17A’s role, however, has yet to be defined. The
report by Nakajima et al. (this issue) begins to define that role by demonstrating
IL-17A’s ability to induce Th2 inflammation in acute disease.
Journal of Investigative Dermatology (2014) 134, 2071–2074. doi:10.1038/jid.2014.141
Atopic dermatitis (AD) is a chronic
inflammatory skin disease characterized
by acute and chronic stages. The patho-
genesis of AD is still unclear; both
immune- and barrier-driven mechan-
isms have been demonstrated in murine
models and in human disease. AD has
been recognized predominantly as a
T helper type 2 (Th2)/Th22-centered
disease (Guttman-Yassky et al., 2011).
Lesional AD skin is characterized pri-
marily by increased expression of Th2
cytokines and chemokines (IL-4/IL-13,
chemokine (C-C motif) ligand (CCL)17,
OX40), Th22-related markers (IL-22), as
well as Th1- (chemokine (CXC motif)
ligand (CXCL10)), Th17- (Elafin/PI3,
CXCL1), and Th17/Th22-mediated S100
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